Literature DB >> 1542935

Sickness behavior as a new target for drug development.

S Kent1, R M Bluthé, K W Kelley, R Dantzer.   

Abstract

Sickness behavior refers to the nonspecific symptoms (anorexia, depressed activity, loss of interest in usual activities, disappearance of body-care activities) that accompany the response to infection. Increasing evidence suggests that these symptoms are part of an organized defense response to antigenic challenge and that they are mediated by the neural effects of cytokines such as interleukin 1. An understanding of the mechanisms involved in these effects should permit development of new drugs aimed at decreasing sickness or promoting recovery processes.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1542935     DOI: 10.1016/0165-6147(92)90012-u

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  146 in total

Review 1.  The central opioid system in liver disease and its complications.

Authors:  C Yurdaydin
Journal:  Metab Brain Dis       Date:  2001-06       Impact factor: 3.584

2.  Short day lengths attenuate the symptoms of infection in Siberian hamsters.

Authors:  Staci D Bilbo; Deborah L Drazen; Ning Quan; Lingli He; Randy J Nelson
Journal:  Proc Biol Sci       Date:  2002-03-07       Impact factor: 5.349

3.  Behavioral and endocrine effects of endotoxin in wild-type mice and mice deficient in interleukin 1: sickness behavior or adaptive response?

Authors:  M P Moshkin; A Tamagawa; I E Kolosova; L A Gerlinskaya; Y Iwakura; Y Endo
Journal:  Dokl Biol Sci       Date:  2001 Jul-Aug

Review 4.  Fatigue in cholestatic liver disease--a perplexing symptom.

Authors:  D Kumar; R K Tandon
Journal:  Postgrad Med J       Date:  2002-07       Impact factor: 2.401

5.  Early maternal separation leads to down-regulation of cytokine gene expression.

Authors:  J J Dimatelis; N S Pillay; A K Mutyaba; V A Russell; W M U Daniels; D J Stein
Journal:  Metab Brain Dis       Date:  2012-04-13       Impact factor: 3.584

6.  Amygdaloid signature of peripheral immune activation by bacterial lipopolysaccharide or staphylococcal enterotoxin B.

Authors:  Geraldine Prager; Martin Hadamitzky; Andrea Engler; Raphael Doenlen; Timo Wirth; Gustavo Pacheco-López; Ute Krügel; Manfred Schedlowski; Harald Engler
Journal:  J Neuroimmune Pharmacol       Date:  2012-05-27       Impact factor: 4.147

Review 7.  Insulin resistance, obesity, inflammation, and depression in polycystic ovary syndrome: biobehavioral mechanisms and interventions.

Authors:  Kristen Farrell; Michael H Antoni
Journal:  Fertil Steril       Date:  2010-05-14       Impact factor: 7.329

8.  Impaired adrenocorticotropic hormone response to bacterial endotoxin in mice deficient in prostaglandin E receptor EP1 and EP3 subtypes.

Authors:  Yoko Matsuoka; Tomoyuki Furuyashiki; Haruhiko Bito; Fumitaka Ushikubi; Yasuhiro Tanaka; Takuya Kobayashi; Seiji Muro; Noriko Satoh; Tetsuro Kayahara; Mikito Higashi; Akira Mizoguchi; Hitoshi Shichi; Yoshihiro Fukuda; Kazuwa Nakao; Shuh Narumiya
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-17       Impact factor: 11.205

Review 9.  Immunoglobulin-mediated neuro-cognitive impairment: new data and a comprehensive review.

Authors:  Assaf Menachem; Joab Chapman; Yael Deri; Chaim G Pick; Aviva Katzav
Journal:  Clin Rev Allergy Immunol       Date:  2013-10       Impact factor: 8.667

10.  Perturbation of chemokine networks by gene deletion alters the reinforcing actions of ethanol.

Authors:  Yuri A Blednov; Susan E Bergeson; Danielle Walker; Vania M M Ferreira; William A Kuziel; R Adron Harris
Journal:  Behav Brain Res       Date:  2005-08-18       Impact factor: 3.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.